News Desk — April 9, 2018 at 8:15 am — Updated: April 9, 2018 at 8:15 am

Novartis bets big on gene therapy with $8.7 billion AveXis deal


ZURICH (Reuters) – Novartis is moving further into gene therapy with a $8.7 billion (£6.17 billion) deal for AveXis that gives the Swiss drugmaker a rare-disease treatment seen reaping billions in sales and bolsters its technology base.

Leave A Comment Using Facebook (Website Comment Form Below)

Use the form below to post a comment via facebook

Leave a Reply

69 queries in 1.088 seconds.